Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 1/20 | 0.41 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711738 | 1.00 | CPB2 (0.47) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL1711732 | 1.00 | CPB2 (0.47) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL1711325 | 1.00 | CPB2 (0.47) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| Hydrochloric Acid SCHEMBL11366046 | 0.99 | CPB2 (0.47) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL31257001 | 0.95 | CPB2 (0.45) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL30284335 | 0.95 | CPB2 (0.45) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL30973961 | 0.93 | FOLH1 (0.56) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL29782763 | 0.92 | FOLH1 (0.51) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL1711315 | 0.92 | FOLH1 (0.54) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL1711313 | 0.92 | FOLH1 (0.54) | CPB2FOLH1ERAP2ERAP1LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100522249-C | Elongated multiple spacers in activatable prodrugs | SINTAGAR B V (NL) | 2009-08-05 | — | — | CN | claimed |
| CN-1511044-A | Elogated and multiple spacers in activatible prodrugs | — | 2004-07-07 | — | — | CN | claimed |
| US-4257940-A | Valylleucyllysine derivatives, process for producing same and method for measuring activity of enzymes using same | TORII & CO., LTD. (JP) | 1981-03-24 | — | — | US | claimed |
| US-11419944-B2 | Non-linear self-immolative linkers and conjugates thereof | BYONDIS B.V. (NL) | 2022-08-23 | — | — | US | disclosed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| CN-106749665-B | Conjugates of CC-1065 analogs and bifunctional linkers | 辛塔佳有限公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-3731874-A1 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | Invivogen (FR) | 2020-11-04 | — | — | EP | disclosed |
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS B.V. (NL) | 2020-09-24 | — | — | US | disclosed |
| EP-3525826-B1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS BV (NL) | 2020-07-22 | — | — | EP | disclosed |
| EP-3108886-B1 | CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | SYNTARGA BV (NL) | 2020-06-17 | — | — | EP | disclosed |
| EP-3525826-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | Synthon Biopharmaceuticals B.V. (NL) | 2019-08-21 | — | — | EP | disclosed |
| WO-2009017394-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2009-02-05 | — | — | WO | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
| EP-1994000-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2008-11-26 | — | — | EP | disclosed |
| EP-1909846-A2 | TRIAZOLE-CONTAINING RELEASABLE LINKERS, CONJUGATES THEREOF, AND METHODS OF PREPARATION | Syntarga B.V. (NL) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007089149-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007018431-A2 | TRIAZOLE-CONTAINING RELEASABLE LINKERS AND CONJUGATES COMPRISING THE SAME | SYNTARGA B.V. (NL) | 2007-02-15 | — | — | WO | disclosed |
| US-4257940-A | Valylleucyllysine derivatives, process for producing same and method for measuring activity of enzymes using same | TORII & CO., LTD. (JP) | 1981-03-24 | — | — | US | disclosed |
| US-4257940-A | Valylleucyllysine derivatives, process for producing same and method for measuring activity of enzymes using same | TORII & CO., LTD. (JP) | 1981-03-24 | — | — | US | disclosed |
| US-4257940-A | Valylleucyllysine derivatives, process for producing same and method for measuring activity of enzymes using same | TORII & CO., LTD. (JP) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | DLST, ADSL, LANCL1 | CPB2 3797/4885FOLH1 736/4885ERAP2 4123/4885 |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | CPB2 1403/4885FOLH1 90/4885ERAP2 3376/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | CPB2 1600/4885FOLH1 603/4885ERAP2 2981/4885 |
| US-11419944-B2 | Non-linear self-immolative linkers and conjugates thereof | DLST, ADSL, LANCL1 | CPB2 3797/4885FOLH1 736/4885ERAP2 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.